High-throughput screening for compounds that restore proper TDP-43 granule dynamics by preventing pathological liquid-to-solid phase transitions, maintaining nuclear function. Highly novel but technically immature with no validated LLPS-modulating pharmacophores or clinical biomarkers.
AAV9-mediated overexpression of LAMP2A enhances chaperone-mediated autophagy to selectively degrade pathological alpha-synuclein species, preventing Lewy body formation and blocking cell-to-cell propagation. Strongest mechanistic foundation with validated AAV platform and clear patient stratification via seed amplification assays.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
AutophagyBiomarkerneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
2/11
dimensions won
Small-Molecule Modulation of TDP-43 Liqu
10/11
dimensions won
LAMP2A-Mediated Autophagy Enhancement Bl
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.55
0.80
Evidence
0.50
0.75
Novelty
0.85
0.70
Feasibility
0.40
0.75
Impact
0.75
0.80
Druggability
0.35
0.70
Safety
0.50
0.65
Competition
0.70
0.75
Data
0.60
0.80
Reproducible
0.45
0.75
KG Connect
0.50
0.50
Score Breakdown
Dimension
Small-Molecule Modulation of T
LAMP2A-Mediated Autophagy Enha
Mechanistic
0.550
0.800
Evidence
0.500
0.750
Novelty
0.850
0.700
Feasibility
0.400
0.750
Impact
0.750
0.800
Druggability
0.350
0.700
Safety
0.500
0.650
Competition
0.700
0.750
Data
0.600
0.800
Reproducible
0.450
0.750
KG Connect
0.500
0.500
Evidence
Small-Molecule Modulation of TDP-43 Liquid-Liquid Phase Sepa